Claudin18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

Download slides, review a text module, listen to a podcast, and read an expert commentary on the rationale and clinical development of therapies targeting claudin18.2 for patients with gastric and GEJ cancers.

Share

Program Content

Activities

Claudin18.2 in G/GEJ: Module
Claudin18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 25, 2023

Expires: April 24, 2024

View Activity
Claudin18.2 in G/GEJ: Slides
Claudin18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 25, 2023

View Activity

Activities

Claudin 18.2 in Gastric Cancer
Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 28, 2023

View Activity

Activities

Claudin18.2 in Gastric Cancer
Considering a Claudin18.2-Targeted Agent in the Current Treatment Landscape for HER2-Negative Gastric Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

View Activity

Faculty

cover img faculity

Gregory Botta, MD, PhD

Clinical Professor of Medicine
Department of Medicine/Hematology & Oncology
University of California San Diego
La Jolla, California

cover img faculity

Samuel Klempner, MD

Associate Professor
Department of Medicine, Division of Hematology-Oncology
Mass General Cancer Center, Harvard Medical Center
Boston, Massachusetts

cover img faculity

Manish Shah, MD

Chief, Solid Tumor Services
Bartlett Family Professor of Gastrointestinal Oncology
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Astellas and Bristol Myers Squibb.

Astellas

Bristol Myers Squibb